Eligibility

Here are the requirements to confirm your eligibility for the project.

  • UK-based SMEs working within the Medicines Manufacturing Sector.  
  • Proposed project aligns with the capabilities a Catapult partner (CPI, Cell and Gene Therapy Catapult, Medicines Discovery Catapult). It is expected that support will be delivered by one Catapult centre, for one SME.  However, it is possible that Catapult centres may collaborate to deliver services to an SME depending on the nature of the support needed by the SME.  
  • SME must be able to receive up to £90,000 Minimal Financial Assistance (MFA) under the Subsidy Control Act 2022 or De Minimis (if applicable under the Windsor Framework for SMEs based in Northern Ireland).  
  • Commercial value of the work must range from £35,000 to £90,000. 
  • Innovation being developed in the project must be between TRL (Technology Readiness Level) 3 and 5  
  • Project work must support the accelerated technical development, business scale-up, commercial readiness or investment potential of the innovation.  
  • The work proposed must take no longer than five months and be completed no later than 31st October 2026.  
CPI is your innovation partner to make your ideas a reality.